![]() |
市场调查报告书
商品编码
1771572
美国美容注射市场规模、份额、趋势分析报告:按产品、应用、最终用途、细分市场预测,2025-2030 年U.S. Aesthetic Injectable Market Size, Share & Trends Analysis Report By Product (Hyaluronic Acid, Botulinum Toxin), By Application, By End-use, And Segment Forecasts, 2025 - 2030 |
预计 2024 年美国美容注射剂市场价值将达到 41 亿美元,预计 2025 年至 2030 年的复合年增长率为 11.2%。
随着消费者期望转向便利性、个人化和预防保健,美国美容注射产业持续发展。注射剂在广泛用户群中的日益普及,以及产品设计的不断进步,正在改变人们对美容疗程的认知和交付方式。 2023年5月,艾尔建美学公司(Allergan Aesthetics)在美国推出了由Juvederm开发的Skinvive,这是一款皮内注射剂,采用基于透明质酸(HA)的微滴,旨在透过增加保湿度和平滑度来改善脸颊皮肤纹理。
非手术美容解决方案的强烈偏好推动了美国美容注射产业的发展。越来越多的消费者选择注射剂,因为它们方便、恢復时间短,并且能够带来自然的效果。这些手术为脸部回春提供了隐藏的选择,避免了手术带来的风险和恢復期。快速治疗和肉眼可见的改善,非常适合寻求细微改善的专业人士和年轻人的生活方式。根据美国整形外科医师协会 (ASPS) 2023 年的数据,男性共进行了 147 万例美容微创手术,其中包括 526,062 次神经调节剂注射和超过 232,000 次填充剂治疗。女性共进行了 1,970 万例美容微创手术,其中包括 820 万例神经调节剂注射和超过 550 万例填充剂治疗。
注射疗法在男性和年轻消费者中越来越受欢迎,他们不仅将注射视为一种矫正措施,更将其视为一种积极主动的自我护理形式。男性通常透过注射来改善脸部特征,而二、三十岁的人则通常透过注射来防止老化的早期迹象。这种人口结构的变化正在扩大基本客群,并促使提供者根据更多样化的人群定制他们的服务和讯息,包括那些寻求保养而非改造的人群。 2024 年 10 月,艾尔建美学公司在佛罗里达州奥兰多举行的 ASDS 年会上展示了新数据,强调了脸部注射剂的安全性和患者满意度。来自美国各地的患者群体参加了此次报告,并强调了治疗效果和社交媒体对患者期望的影响。
持续的技术创新正在塑造注射剂市场的竞争格局。新产品的设计旨在延长使用寿命,与皮肤更加无缝融合,并提供更自然的动态和外观。这些进步使治疗对初次就诊和復诊患者更具吸引力。差异化配方和针对性应用的发展使品牌能够更精准、更可靠地解决特定的美学问题。 2025年1月,高德美公司宣布了美国临床试验的积极中期结果,该试验评估了Sculptra联合治疗瑞蓝治疗药物性减肥相关的面部体积减少的效果。试验结果显示,患者获得了显着的美学改善和较高的满意度。一项为期六个月的延伸研究正在进行中,以评估长期疗效。
The U.S. aesthetic injectable market size was estimated at USD 4.1 billion in 2024 and is projected to grow at a CAGR of 11.2% from 2025 to 2030. The U.S. aesthetic injectable industry continues to evolve as consumer expectations shift toward convenience, personalization, and preventative care. The growing popularity of injectables among a broader range of users, along with advances in product design, is changing the way cosmetic treatments are perceived and delivered. In May 2023, Allergan Aesthetics launched Skinvive by Juvederm in the U.S., an intradermal HA-based microdroplet injection designed to improve cheek skin quality by enhancing hydration and smoothness.
A strong preference for non-surgical cosmetic solutions drives the U.S. aesthetic injectable industry. Consumers are increasingly choosing injectables due to their convenience, short recovery time, and ability to deliver natural-looking results. These procedures offer a discreet option for facial rejuvenation without the risks or downtime associated with surgery. The appeal of quick treatments with visible enhancements fits nicely into the lifestyle of professionals and younger individuals seeking subtle improvements. According to the American Society of Plastic Surgeons (ASPS) 2023 data, 1.47 million cosmetic minimally invasive procedures were performed on males, including 526,062 neuromodulator injections and over 232,000 filler treatments. For females, the number reached 19.7 million, with 8.2 million neuromodulator injections and over 5.5 million filler procedures.
Injectable treatments are growing in popularity among men and younger consumers, who view them not just as corrective tools but as a form of proactive self-care. Men are turning to injectables to refine facial features, while individuals in their 20s and 30s often use them to prevent early signs of aging. This shifting demographic has broadened the customer base and encourages providers to tailor services and messaging to a more diverse audience, including those looking for maintenance rather than transformation. In October 2024, Allergan Aesthetics presented new data at the ASDS Annual Meeting in Orlando, Florida, highlighting safety and patient satisfaction with facial injectables. The presentations included diverse patient demographics across the U.S., emphasizing treatment efficacy and social media's impact on patient expectations.
Ongoing innovation is shaping the competitive edge of the injectable market. New products are designed to last longer, integrate more seamlessly with skin, and provide more natural movement and appearance. These advancements make treatments more appealing to first-time users and returning clients. With the development of differentiated formulations and targeted applications, brands can address specific aesthetic concerns with greater precision and reliability. In January 2025, Galderma announced positive interim results from a U.S.-based trial evaluating Sculptra combined with Restylane for treating facial volume loss caused by medication-driven weight loss. The study showed significant aesthetic improvements and high patient satisfaction. A six-month extension is ongoing to assess long-term effects.
U.S. Aesthetic Injectable Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. aesthetic injectable market report based on product, application, and end-use: